<SEC-DOCUMENT>0001558370-23-015582.txt : 20230908
<SEC-HEADER>0001558370-23-015582.hdr.sgml : 20230908
<ACCEPTANCE-DATETIME>20230908091222
ACCESSION NUMBER:		0001558370-23-015582
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230908
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230908
DATE AS OF CHANGE:		20230908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		231243803

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>chrs-20230908x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 9/7/2023 9:30:54 PM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: 2d702ed6-316e-4b93-815b-591aadad20cd -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:chrs="http://www.coherus.com/20230908" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityCentralIndexKey" id="Tc_P2YpwIk-nkSRMqz8olCmtw_2_1">0001512762</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:AmendmentFlag" id="Tc_BOnlIVN_802s6wzKHsDE3w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="chrs-20230908.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:9.77pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_c3444169_3022_4333_ba87_25468991b09d"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:DocumentType" id="Narr_QB_sdfBndUiVWfp24GFeoQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_o5kwa5VamE2clVkroPQxDw"><b style="font-weight:bold;">September 8, 2023</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:24pt;font-weight:bold;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityRegistrantName" id="Narr_V9FIXCfXVUqm24EzOOQOJw">COHERUS BIOSCIENCES, INC.</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_4fef730f_4ab3_41d5_9b95_011d505ca620"></a><a id="Tc_H5vTAeemZ0qglzHC4O5uQA_1_0"></a><a id="Tc_kZJ_cM_m_k-Lb5pcOku4Tg_1_2"></a><a id="Tc_z6gzRI-Zbki0z99o21pC0g_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_aVb8eMIFq0K-2UjXhfylBw_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityFileNumber" id="Tc_t8jsZ-0RO0SD7JBS9JS3mw_0_2"><b style="font-size:9pt;font-weight:bold;">001-36721</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityTaxIdentificationNumber" id="Tc_pDUIKHEgY0Klu_fmsA5nfA_0_4"><b style="font-size:9pt;font-weight:bold;">27-3615821</b></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br /><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><br /><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityAddressAddressLine1" id="Narr_klPlshZT4UiJf-rI5FbCCA"><b style="font-weight:bold;">333 Twin Dolphin Drive</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityAddressAddressLine2" id="Narr_Z4JrzkpTiUW3q9lt1nFF_g"><b style="font-weight:bold;">Suite 600</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityAddressCityOrTown" id="Narr_g336XkdcWEOogGu7w9AViA"><b style="font-weight:bold;">Redwood City</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityAddressStateOrProvince" id="Narr_8l8Pb6SPoUSCSIXyWr8siw"><b style="font-weight:bold;">CA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:EntityAddressPostalZipCode" id="Narr_1AFXhMKqbU619vzdAcDwCA"><b style="font-weight:bold;">94065</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:CityAreaCode" id="Narr_9lEPBIQsxkW0TymT8beK0A"><b style="font-weight:bold;">650</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:LocalPhoneNumber" id="Narr_-XaMmHfrQE61-tGjAo91EQ"><b style="font-weight:bold;">649-3530</b></ix:nonNumeric></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_1df92469_f3ff_4402_ae86_b7c37a7d26ea"></a><a id="Tc_TjyDAiPJMEWYYIj6GpfO_w_0_1"></a><a id="Tc_9Pa4au_2_kSpbNhO9k3xcA_2_1"></a><a id="Tc_0WJ5Un_pYU2zaRwjSpiNWg_4_1"></a><a id="Tc_KvUW1yzMB0O5nSFuQfjJeA_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_ITJy0beGqUmPlNtsa00Vfw_0_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_OWNrFJh23keZCCE4rXo8Xw_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_xPaw7PCBrkuHSNeLC_Bu7g_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_CkfBlsTf9Eq7BGBCa5-Q2g_6_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_132bb9e4_a733_46a7_a748_975eae4dea5f"></a><a id="Tc_GEiERFp0i0iHf-ldEEM-sA_0_0"></a><a id="Tc_fUq23arpVU60XYfKHdLhJw_0_2"></a><a id="Tc_Mnxv0m6PQ0e9vvn4bFNfXw_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b><br /><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange</b><br /><b style="font-weight:bold;">on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:Security12bTitle" id="Tc_Qj35AmDBUE6JrFPbxEyKpQ_1_0"><b style="font-weight:bold;">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" name="dei:TradingSymbol" id="Tc_Z3NuZ7Zc2k2TlK1ap1OrjQ_1_2"><b style="font-weight:bold;">CHRS</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_Jgk89qBnl0ODlS22CwRsvw_1_4"><b style="font-weight:bold;">The Nasdaq Global Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_0iVcUMK7rEGUKq5-YUMrAg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_5e01471f_f26e_409e_9a79_4be35dc1b509"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Introductory Note</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">As previously announced, on June 15, 2023, Coherus BioSciences, Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;) by and among the Company, Crimson Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub I</span>&#8221;), Crimson Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub II</span>&#8221; and together with Merger Sub I, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Subs</span>&#8221;), and Surface Oncology, Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</span>&#8221;).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">On September 8, 2023, the Company completed the previously announced acquisition of Surface pursuant to the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub I merged with and into Surface (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger</span>&#8221;), with Surface surviving such First Merger as a wholly owned subsidiary of the Company, and, as part of the same overall transaction, promptly after the First Merger, the surviving entity of the First Merger merged with and into Merger Sub II (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Merger</span>&#8221; and together with the First Merger, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mergers</span>&#8221;), with Merger Sub II surviving the Second Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Entity</span>&#8221;). The Mergers became effective on September 8, 2023 upon the filing of the Certificate of Merger for the First Merger with the Secretary of the State of Delaware (the time of the filing of the Certificate of Merger for the First Merger, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>&#8221;). Additionally, on September 8, 2023, in connection with the Merger Agreement, the Company and Computershare Trust Company, N.A., as rights agent, entered into a contingent value right (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CVR</span>&#8221;) agreement, pursuant to which each share of common stock, $0.0001 par value per share, of Surface (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Common Stock</span>&#8221;) issued and outstanding immediately prior to the Effective Time (other than treasury shares, any shares of Surface Common Stock held directly by the Company or Merger Subs immediately prior to the Effective Time and shares of Surface Common Stock issued and outstanding immediately prior to the Effective Time and held by any holder who properly demands appraisal for such shares in accordance with Section 262 of the Delaware General Corporation Law) were entitled to one CVR. Each CVR entitles the holder thereof to receive contingent payments of cash and/or common stock, par value $0.0001 per share, of the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Common Stock</span>&#8221;) upon the achievement of certain sales milestones related to Surface&#8217;s product candidates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">The following events took place in connection with the completion of the Mergers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 2.01 Completion of Acquisition or Disposition of Assets</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">The information included in the Introductory Note is incorporated herein by reference into this Item 2.01.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Merger Consideration</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">Under the Merger Agreement, at the Effective Time of the First Merger, each share of Surface Common Stock issued and outstanding immediately prior to the Effective Time (other than&#160;treasury shares, any shares of Surface Common Stock held directly by the Company or Merger Subs immediately prior to the Effective Time and shares of Surface Common Stock issued and outstanding immediately prior to the Effective Time and held by any holder who properly demands appraisal for such shares in accordance with Section&#160;262 of the Delaware General Corporation Law) was converted automatically into the right to receive consideration per share consisting of:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">0.1960 (the &#8220;</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Ratio</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shares of Company Common Stock, plus any cash payable in lieu of a fractional share of Company Common Stock (the &#8220;</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Upfront Consideration</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); and</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 60.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one CVR representing a contractual right to receive future conditional payments, settleable in cash, additional shares of Company Common Stock or a combination of cash and additional shares of Company Common Stock, at the Company&#8217;s sole discretion (and subject, in each case, to deduction for any required withholding taxes), upon the achievement of certain sales milestones related to Surface&#8217;s product candidates. </span></td></tr></table></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">At the Effective Time, each option (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Stock Option</span>&#8221;) to purchase Surface Common Stock granted under Surface&#8217;s equity incentive plans that is outstanding immediately prior to the Effective Time was converted, assumed or cancelled as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">each Surface Stock Option with an exercise price per share that was less than the value of the Upfront Consideration (an &#8220;</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In-the-Money&#160;Option</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) was cancelled and converted into the right to receive:</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a number of shares of Company Common Stock, subject to certain exceptions for fractional shares and applicable withholdings, equal to the quotient of (x)&#160;the product of (1)&#160;the total number of shares of vested and unvested Surface Common Stock underlying the&#160;In-the-Money&#160;Option multiplied by (2)&#160;the excess of the value of the Upfront Consideration over the exercise price of such&#160;In-the-Money&#160;Option, divided by (y)&#160;$5.2831; and</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a number of CVRs equal to the vested and unvested shares of Surface Common Stock underlying the&#160;In-the-Money&#160;Option;</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">each Surface Stock Option held by a Surface employee who continued employment with the Company and its affiliates after the Effective Time (a &#8220;</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Employee</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and with an exercise price that is equal to or greater than the value of the Upfront Consideration (each, an &#8220;</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Underwater Option</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) was assumed by the Company and converted into an option to acquire shares of Company Common Stock (an &#8220;</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumed Option</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and with the same vesting schedule and other terms and conditions applicable to such Assumed Option immediately prior to the Effective Time, except that (i) each Assumed Option became exercisable for a number of shares of Company Common Stock equal to the product (rounded down to the next whole number of shares) of (x) the number of shares of Surface Common Stock that would have been issuable upon full exercise of such Assumed Option immediately prior to the Effective Time multiplied by (y) the Exchange Ratio, and (ii) the per share exercise price for such Assumed Option equals the quotient (rounded up to the next whole cent) obtained by dividing the exercise price per share of the Surface Common Stock as of immediately prior to the Effective Time by the Exchange Ratio; and</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 37.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:19.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">each Underwater Option held by a Surface employee who is not a Covered Employee was cancelled, and the holder of such Underwater Option received no Merger Consideration with respect to such Underwater Option.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">At the Effective Time, each Surface restricted stock unit award (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface RSU Award</span>&#8221;), whether vested or unvested, that was outstanding immediately prior to the Effective Time was automatically converted into the right to receive the Merger Consideration in respect of each share of Surface Common Stock subject to such Surface RSU Award, subject to certain exceptions for fractional shares and applicable withholdings.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">The issuance of Company Common Stock in connection with the Mergers was registered under the Securities Act of 1933, as amended, pursuant to the Company&#8217;s Registration Statement on Form S-4, as amended (Registration No. 333-273179), declared effective by the U.S. Securities and Exchange Commission (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</span>&#8221;) on July 26, 2023. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">The foregoing description of the Merger Agreement and the Mergers does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, a copy of which was attached as&#160;Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 16, 2023, the terms of which are incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_da5081c9_31f1_4e13_84dd_330effafb5c2"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 8.01 Other Events.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">On September 8, 2023, the Company issued a press release announcing the completion of the Mergers. A copy of the press release is attached as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8e438b73_fcdd_4464_bc17_5c8004c82f3d"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">(a) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements of Business Acquired</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;">As permitted by Item 9.01(a)(3)&#160;of Form&#160;8-K, the financial statements required by this Item will be filed by amendment to this Current Report on Form&#160;8-K within 71 days following the date on which this Current Report on Form&#160;8-K is required to be filed.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;(b) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Forma Financial Information</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;">As permitted by Item 9.01(a)(3)&#160;of Form&#160;8-K, the pro forma financial statements required by this Item will be filed by amendment to this Current Report on Form&#160;8-K within 71 days following the date on which this Current Report on Form&#160;8-K is required to be filed.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(d) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span>. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.99938583%;width:101.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:80%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:17.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:80%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/d523169dex21.htm"><span style="font-style:normal;font-weight:normal;">Agreement and Plan of Merger, by and among Coherus BioSciences, Inc., Crimson Merger Sub I, Inc., Crimson Merger Sub II, LLC and Surface Oncology, Inc., dated June 15, 2023 (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed on June 16, 2023)</span></a></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:17.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20230908xex99d1.htm"><span style="font-style:normal;font-weight:normal;">Press Release of Coherus BioSciences, Inc., dated September 8, 2023</span></a></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:17.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_084f5285_16b0_4eb0_a16c_0bf9270f84b7"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.45pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: September 8, 2023</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">COHERUS BIOSCIENCES, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ McDavid Stilwell</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">McDavid Stilwell</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>chrs-20230908xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/7/2023 09:30:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:20pt;line-height:1.17;background:#ffffff;margin:0pt;"><img src="chrs-20230908xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:68.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:124.95pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:8pt;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;line-height:1.17;text-align:center;background:#ffffff;margin:0pt;"><font style="font-size:20pt;"><a name="_z7yconokz22h"></a></font><b style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Coherus Completes Surface Oncology Acquisition</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><i style="color:#0a0a0a;font-style:italic;"> </i><i style="color:#0a0a0a;font-style:italic;background:#ffffff;">&#8211;</i><i style="color:#0a0a0a;font-style:italic;"> Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><i style="color:#0a0a0a;font-style:italic;">next-generation immuno-oncology portfolio focused on the tumor microenvironment &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:6pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="color:#0a0a0a;font-style:italic;background:#ffffff;">&#8211; I-O combinations will potentially expand toripalimab opportunity into large indications with high unmet need &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><font style="color:#0a0a0a;">REDWOOD CITY, Calif., September 8, 2023 -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc. (Surface or Surface Oncology), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. As a result of the acquisition, Coherus&#8217; novel I-O pipeline now includes four differentiated clinical-stage assets: </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Toripalimab, a late-stage, anti-PD-1 monoclonal antibody candidate under BLA review for the potential treatment of advanced recurrent or metastatic nasopharyngeal carcinoma (NPC); </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Casdozokitug (SRF388 or casdozo), a novel, first-in-class IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">CHS-114 (SRF114), a highly selective, competitively positioned, ADCC-enhanced CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#0a0a0a;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">CHS-006, a TIGIT-targeted antibody currently in a Phase 1/2 study in combination with toripalimab in patients with advanced solid tumors.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">&#8220;The addition of the first-in-class IL-27 targeted antibody, casdozo, and the potential best-in-class CCR8 targeted antibody CHS-114, marks Coherus&#8217; transition to a next-generation immuno-oncology company focused on the tumor microenvironment,&#8221; said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. &#8220;We will now </font><font style="color:#0a0a0a;">focus our development efforts on delivering breakthrough survival benefits for cancer patients, beyond the efficacy seen with existing chemotherapy plus checkpoints regimens. Toripalimab combinations with these two new agents have the potential to expand tori use into highly prevalent tumor types including NSCLC and head and neck cancer, where it has already consistently shown clinically meaningful activity.</font><font style="color:#0a0a0a;">&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">At the closing of the acquisition, Coherus issued 0.1960 shares of its common stock per share of outstanding Surface common stock and certain outstanding Surface employee equity awards (which exchange ratio was calculated based on a $5.2831 per share price of Coherus common stock) for a total value equal to approximately $66.9 million, the sum of $40 million plus Surface&#8217;s net cash at closing of the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">transaction of $26.9 million. Surface shareholders also received contingent value rights (CVRs) for 70% of milestone and royalty-based value of existing programs with Novartis (NZV930) and GSK (GSK4381562), as well as for 25% of upfront payments made pursuant to potential ex-US licensing agreements for CHS-114 and 50% of upfront payments made pursuant to potential ex-US licensing agreements for casdozokitug, subject to certain deductions as set forth in the contingent value rights agreement. Amounts under these CVRs are payable for a period of ten years following the closing of this transaction. As a result of the acquisition, Surface has become a wholly owned subsidiary of Coherus and the common stock of Surface will no longer be listed for trading on the Nasdaq Capital Market, effective as of prior to market open on September 8, 2023.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">Truist Securities acted as financial advisor, and Arnold &amp; Porter Kaye Scholer LLP and Latham &amp; Watkins LLP acted as legal advisors to Coherus. Wedbush Securities Inc. acted as exclusive strategic financial advisor, and Goodwin Procter LLP acted as legal advisor to Surface.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="color:#0a0a0a;font-weight:bold;">About Coherus&#8217; Immuno-Oncology Pipeline</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">Coherus is developing an innovative immuno-oncology pipeline that will be synergistic with its proven commercial capabilities in oncology. Through an in-licensing agreement with Shanghai Junshi Biosciences Ltd., Coherus is developing toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of NPC is under review by the FDA. Toripalimab is approved in China for the treatment of melanoma, urothelial cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and non-small cell lung cancer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">Through its acquisition of Surface Oncology, Coherus&#8217; immuno-oncology pipeline will now include multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug (SRF388) is a novel anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 (SRF114) is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors. There are also two out-licensed partnership programs to advance its next-generation cancer therapies.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">Coherus&#8217; earlier-stage immuno-oncology pipeline targets immune-suppressive mechanisms in the tumor microenvironment, including CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 clinical trial in combination with toripalimab in patients with advanced solid tumors, and CHS-1000, a preclinical program targeting the novel pathway ILT4.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;background:#ffffff;margin:0pt;"><b style="color:#0a0a0a;font-weight:bold;">About Coherus BioSciences</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus&#8217; strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="color:#0a0a0a;">In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma is currently under review by the FDA.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><font style="color:#0a0a0a;">Coherus markets UDENYCA&#174; (pegfilgrastim-cbqv), a biosimilar of Neulasta&#174;, CIMERLI&#174; (ranibizumab-eqrn), a biosimilar of Lucentis&#174;, and YUSIMRY&#8482; (adalimumab-aqvh), a biosimilar of Humira&#174;.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;">Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus&#8217; ability to build its immuno-oncology franchise to achieve a leading market position; Coherus&#8217; ability to generate cash and net sales; Coherus&#8217; investment plans; Coherus&#8217; ability to find synergies between its I-O pipeline and its commercial operations; expectations about the efficacy and safety profile of any product candidate in the future; and Coherus&#8217; ability to expand toripalimab into highly prevalent tumor types, to further advance its next-generation immuno-oncology portfolio focused on the tumor microenvironment, and to improve survival outcomes in cancer treatment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;">Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus&#8217; actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to integration of Surface&#8217;s programs and operations; risks related to realizing the anticipated benefits of the acquisition of Surface; risks related to Coherus&#8217; existing and potential collaboration partners; risks of Coherus&#8217; competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus&#8217; business and the timing of Coherus&#8217; regulatory filings; the risk of FDA review issues; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus&#8217; products and product candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus&#8217; business in general, see Coherus&#8217; Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 filed with the Securities and Exchange Commission on August 2, 2023, including the section therein captioned &#8220;Risk Factors&#8221; and in other documents Coherus files with the Securities and Exchange Commission. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;">UDENYCA&#174;, CIMERLI&#174; and YUSIMRY&#8482;, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Coherus Contacts</b><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Marek Ciszewski, SVP Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">IR@coherus.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Media Relations:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Jodi Sievers, VP Corporate Communications</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">media@coherus.com</u></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>chrs-20230908xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20230908xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "* /H# 2(  A$! Q$!_\0
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MQ,\C-G& H&:_2O\ 8Z_9>;X*Z/-K_B&.-O%^HQ"-HU(86,.0?*![L2 6(XX
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M<5ZS\*M$U#PS\,_">D:LJ)J5AI5K:W*QMN42)$JL >_(ZUU/6O.OV@OB_:_
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MWMTSD#+L[DD$?(*]@3_@FPND?&S0I+?4&U7X=!C<W@NV47*%,$0-C <2' W
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M?B-,#GB3Q!N_G'6%J/\ P3@^&NKW)N+[7O%]Y.0%,MQJ44C8],F$FM']F/\
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MW?;^^./S K[^K\^/^"66LV\.H?$'3'<+<RQ6=PBD\LBF56('L77\Z_08'(H
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M)DMRVXPRJ2LB9[X8$ ]Q@UW%?(_P)^(%A^R[^SAX)T_Q;;7K:IJ"RWYL[:-
MUO%-*S(96D=%3.5 !;).<#Y6QZXO[5/PXC4)>ZS/IUXHQ-9W5A.LL#_Q1N A
M 93D$ GD'F@#URO.OBO^S]X$^--L$\5:#!>72+MBOXLQ7,8]!(O)'L<CVKT6
MB@#XA\0_\$N?#5W<;]$\:ZGID623'>6<=R?;#*R8Q]#5GPI_P3 \)Z==++XA
M\6ZIKD:L"(+6!+12.X8DN?RQ7VK10!S/P^^&OAKX6:!%HOA?2+?2-/3DI"OS
M2-_>=C\SM[DFNFHHH \>^-G[*G@#X[-]KUW3GM-:";%U?3F$5Q@= W!5P/\
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M6CO6EV\E BJ"#CIZD@5B:=\8/B1-#8:O<_":X/A^],;!;+5H9M0AC?&'DM\
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(FD'04M '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>chrs-20230908.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/7/2023 9:31:02 PM-->
<!--Modified on: 9/7/2023 9:31:02 PM-->
<xsd:schema targetNamespace="http://www.coherus.com/20230908" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:chrs="http://www.coherus.com/20230908">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20230908_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20230908_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20230908_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="chrs_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>chrs-20230908_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/7/2023 9:31:02 PM-->
<!--Modified on: 9/7/2023 9:31:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="chrs-20230908.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>chrs-20230908_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/7/2023 9:31:02 PM-->
<!--Modified on: 9/7/2023 9:31:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="chrs-20230908.xsd#chrs_DocumentAndEntityInformationAbstract" xlink:label="chrs_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="chrs_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>chrs-20230908_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/7/2023 9:31:02 PM-->
<!--Modified on: 9/7/2023 9:31:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="chrs-20230908.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20230908.xsd#chrs_DocumentAndEntityInformationAbstract" xlink:label="chrs_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638297190622766359" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638297190622766359" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638297190622766359" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638297190622766359" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638297190622766359" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638297190622766359" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638297190622766359" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638297190622766359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638297190622766359" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638297190622776346" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638297190622776346" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638297190622776346" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638297190622776346" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638297190622776346" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638297190622776346" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638297190622776346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638297190622776346" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638297190622786581" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638297190622786581" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638297190622786581" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638297190622786581" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638297190622786581" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638297190622786581" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638297190622786581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638297190622786581" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638297190622796338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638297190622796338" order="23" use="optional" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140266860297728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COHERUS BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  08,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>chrs-20230908x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="chrs-20230908.xsd" xlink:type="simple"/>
    <context id="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_P2YpwIk-nkSRMqz8olCmtw_2_1">0001512762</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_BOnlIVN_802s6wzKHsDE3w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_QB_sdfBndUiVWfp24GFeoQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_o5kwa5VamE2clVkroPQxDw">2023-09-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_V9FIXCfXVUqm24EzOOQOJw">COHERUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_aVb8eMIFq0K-2UjXhfylBw_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_t8jsZ-0RO0SD7JBS9JS3mw_0_2">001-36721</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_pDUIKHEgY0Klu_fmsA5nfA_0_4">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_klPlshZT4UiJf-rI5FbCCA">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_Z4JrzkpTiUW3q9lt1nFF_g">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_g336XkdcWEOogGu7w9AViA">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_8l8Pb6SPoUSCSIXyWr8siw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_1AFXhMKqbU619vzdAcDwCA">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_9lEPBIQsxkW0TymT8beK0A">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_-XaMmHfrQE61-tGjAo91EQ">649-3530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_ITJy0beGqUmPlNtsa00Vfw_0_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_OWNrFJh23keZCCE4rXo8Xw_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_xPaw7PCBrkuHSNeLC_Bu7g_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_CkfBlsTf9Eq7BGBCa5-Q2g_6_0">false</dei:PreCommencementTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_Qj35AmDBUE6JrFPbxEyKpQ_1_0">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_Z3NuZ7Zc2k2TlK1ap1OrjQ_1_2">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Tc_Jgk89qBnl0ODlS22CwRsvw_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ"
      id="Narr_0iVcUMK7rEGUKq5-YUMrAg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MBDDH5S&.9>_N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ BDDH5YE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "*22A7$=MQ
MM7<$  !Z$0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ BDDH5Y^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  &A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="chrs-20230908x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="chrs-20230908x8k.htm">chrs-20230908x8k.htm</File>
    <File>chrs-20230908.xsd</File>
    <File>chrs-20230908_def.xml</File>
    <File>chrs-20230908_lab.xml</File>
    <File>chrs-20230908_pre.xml</File>
    <File>chrs-20230908xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "chrs-20230908x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "chrs-20230908_def.xml"
     ]
    },
    "inline": {
     "local": [
      "chrs-20230908x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20230908_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20230908_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "chrs-20230908.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20230908",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20230908x8k.htm",
      "contextRef": "Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20230908x8k.htm",
      "contextRef": "Duration_9_8_2023_To_9_8_2023_a-_ho_Dyq0SKDqtht6rVtQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "chrs_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.coherus.com/20230908",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-015582-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-015582-xbrl.zip
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M&W%%'V[7<7IM9%3'E:*SJVZA%NBYL?GVWN7)N9'-*,U>@+O\!U!+ P04
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M2?=%- X>WMJ!W;8=8)I(XJ#X?_ZJ*)+Z^DT!7X/1ZB^-$M/=7*2=I<7;2;F
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MS1QO2&R1%G'D^3U2R1T3"R #A,P.0.)"YIK,Q'R/P.X-G)"ZS!L$SH@$T-W
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MNF4^=1QAEU)N+^ZA-=GKASA8J+**=4JI3XN1'K=-'*815YMIY$S:9S!F(R,
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MQ&8Q 0%N]B-WWNQZ\INPA#,!VX@#[X_98AHU28GVG !N3'_H>@A8QST'D8/
MAA$84M_<8'3WHGE%]K$-TPM9HZWV(F\'P&SL^=@;QYF>&J+-)O\N$/-(9YMG
M^<IV$ZZ*-^]].*<\Y5+F/#A%BJ5[G=>Z\.$IGIQM$:W4@A34EUSC_GS)!Y?
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M<C"VF*=090(Y7^^0KH\'YW7#L!]4"X7A<)B'<OF.=UO8]XTN3%9!@9D=ZA?
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M\;U&S;^+9%0B"C8(<]VV^EE$>81/$IV!K"V :'P;Q3\KE<RIRJA5;"L"-])
M) 3U^H])^$YQ;CL*LWJVY7@$]+2>.IWXU*@^W7(6NGR?_6C+?:CS$I@V.ZG(
MUF2>([0X4[]QE*%J<[J&JO,J\"5F@61R0D$J]J&),"V"U4RXXD(FM%.TF!?<
MG<&1+A-AU:S(B$(^YA:/-H0"/^T%857DE.S7,C=326UM$]K:[-0F[2;8;N[)
MKO2W\D93:YF#AVCQ)I>D[!>63K#XO)7G/.%PW6PDB5P9FQ"L!"'9-)PX\)ZT
MD=E5#;"5MM>KLR'1Y@--Z)2-%F[<BV?'JZDAQCFD//-U?^3/.=\\:P;@1;VQ
M%BLU):"IY[9/Y(3KH[DFF@$"1Z@SK@JY;*FU;F^VN;10Y9').#U!CS6:#'\?
MSQ[TC_3VSI,,:S[B5A.I2QCA. #+$/5ED8IEX:9Y3*'1337-VHNO<U?H K9)
M[5:2"[2R6!JI(%A1  0)%QQ$[D +P(9";+!A):>^]4 W2RBC4^Y(<,-CKM6*
M7Q VV]3H>NC4-!R$<';EJUP?TLNB8N1MW:SU-E:;K3<// 'OWS[P5+I*VF?N
M%9!?HR(*H4B7(%!1!WP.#@ZC"P!XN$[XLF()[BE#]M,Y?5POUX7J5'VVY6]C
MA&MV!6B=2J2YFT\"+0.1JX::8 21*>$RA7%@)Q-4W) F,Y5WOZ6&V2B+W5U0
M;VU29'ZK*G^B GMK>7ZRV^T2>=AFO5+0G<",RE=XH\3DTSE?L)/3RT?WHBN?
M"Y0U3[']W0 8;^"DH/% &Q22,P2?TC6S;BO,0]UA*_&TM5+]=G7!>D[YCE<!
M[0:Z:YR24QY7+'WMJDF&[&%!%&/LJ)1(;CC2 I\_KMOH&)EOC!08N3,!GJ2*
M)DA5@C]S!PQ]Z*5:GN'ILB::D-<W<BS)3]8G:'$30"FJ@9$GWG'H[^,)3W)*
MG'L-.)LO8\8G ;/4K?JIAK.G <X>;X&SF]S82L.#FP8HI:<_^&07M&H9B&^#
MR%\+NW_/PNYG/3)=V9$O51GVYMGS5W\,C[__IG?P:, >%&(REBDB*-;-HGCT
M=N:.I, #&XG]<=>D?"7*E%38/P3;/'GY_/STI)H#ODZ.Y+L2MA*)MSK?,,-I
M26?JI:EF((/\X\W%R<OS/^!A'QWN8AI8)^S-S<+?SJ8;9OFES*0.5-R+Q[O]
M'8EM;]&]4)HZ3=&I0L) _2AR0JZJ^]EC]P95NG4/SZ]C4=@ZK4:T(J<7.]PV
MIE,6'G-C12XI>2! +T.;"C<M%?_72LZ2:A^ H'!>,"WC\?\XL",-[# U.YPK
M#0X[=%"KTO#W;TME!X:/J2"LX1W\!5=:08I*%>\P\DS+&>6%C1+@*7Y,//GG
M@K;"CF-7+>@='3UN0%[@66 LP #D69F+%U:UFO1I,0'E#AROP@%?S%DLH8"L
M</A&$$!Y#3X)JB#7F"$4CRM7,]BR1H490LO/-:P#9KCQF,QGPOA05*10G6WS
MCB6F"B4L065W.Z?>/FUFY60_K5@U:T-%2Q4A*\,"XKI ZADZ^=P!UY4# _0X
MB=)2;U[!W[C>#N&Y&Z].5?%[7-I2BX&/W+?2O^']F#L/ K3<QDM-P7MKMOF1
M[S*%(RT*\SC MCQQ4=<;Y#*EK>!#^XMQ#Q=E/-UFN] SE;IMC:CS[OI96IHK
MC[;HU1C7H[+U.RBQ*F$H,:?C&NLBC2TUR'UW"!*";CD/E/OW98+M^'7!4?]:
MR=J;=&.M,J=37G7>;S(H$/DKDJ4F0:4$N0/DNGWOU D%<V[;;2AZ00$R11Z-
M-,UXOWG[(U/WGDS=N:O2VT27DY7D!KJ$)!!&YZ=R^$1X/<N1H&B^5KVK3PS4
M119:O6F]-R:"+B)KJE)I$FT,\W*G(JJS0C<;>(TE-TRY7N"HVKI$R[(=ZHY^
MPM?[/505HFJZ9<^OFJ91YVJXT6U\#G3#K],Y#Z47H<[L"PG$V&9%Q!W(*.CM
M.3S7>,9#\Y;CN/99 36'#'G!372.2@-+-,M>);!6B'5K(QN+P$UBC%GN)R2
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M   1              "  0    !C:')S+3(P,C,P.3 X+GAS9%!+ 0(4 Q0
M   ( (I)*%<T2B!_) ,  %0,   5              "  6P$  !C:')S+3(P
M,C,P.3 X7V1E9BYX;6Q02P$"% ,4    " "*22A79!\N,)T%  "//@  %0
M            @ '#!P  8VAR<RTR,#(S,#DP.%]L86(N>&UL4$L! A0#%
M  @ BDDH5__RO=O4!   +"P  !4              ( !DPT  &-H<G,M,C R
M,S Y,#A?<')E+GAM;%!+ 0(4 Q0    ( (I)*%>A-JJV72   !CP   4
M          "  9H2  !C:')S+3(P,C,P.3 X>#AK+FAT;5!+ 0(4 Q0    (
M (I)*%?1Z.@GBQ,  !=0   8              "  2DS  !C:')S+3(P,C,P
D.3 X>&5X.3ED,2YH=&U02P4&      8 !@"0 0  ZD8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
